drugset / Trial / NCT02849587

The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking

NCT02849587

Phase 1/2 Completed 199 enrolled University of California, San Diego
RandomizedParallel-groupTriple-blindScreening

Summary

This study was authorized by the California Legislature (Assembly Bill 266, the Medical Marijuana Regulation and Safety Act to help with detection of driving under the influence of cannabis. One hundred and eighty healthy volunteers will inhale smoked cannabis with either 0% (placebo), 5.9%, or 13.4% Δ9-tetrahydrocannabinol (THC) at the beginning of the day, and then complete driving simulations, iPad-based performance assessments, and bodily fluid draws (e.g., blood, saliva, breath) before the cannabis smoking and a number of times over the subsequent 6 hours after cannabis smoking. The purpose is to determine (1) the relationship of the dose of Δ9-THC on driving performance and (2) the duration of driving impairment in terms of hours from initial use, (3) if saliva or expired air can serve as a useful substitute for blood sampling of Δ9-THC, and (4) if testing using an iPad can serve as a useful adjunct to the standardized field sobriety test in identifying acute impairment from cannabis.

Timeline

Start
2017-02-24
Primary completion
2019-06-17
Completion
2019-06-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabis Traditional medicine (herbal / TCM) 5.9 % Inhaled
Subject Cannabis Traditional medicine (herbal / TCM) 13.4 % Inhaled

Indications